Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard J Federoff

Showing results (21-30 of 164) with videos related to

Pageof 17
Sort By:
Experimental Neurology|March 26, 2013
Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?Massimo S Fiandaca, Howard J Federoff
Science Translational Medicine|September 30, 2011
Disclosure of clinical trial results when product development is abandonedMichael A Rogawski, Howard J Federoff
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 3, 2014
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH directorHoward J Federoff, John E Wagner
Technology and Innovation|April 19, 2014
EDITORIAL: TECHNOLOGY, INNOVATION, AND HEALTHPaul R Sanberg, Howard J Federoff
Technology and Innovation|September 26, 2014
TECHNOLOGY AND INVENTIONPaul R Sanberg, Howard J Federoff
Current Opinion in Molecular Therapeutics|November 13, 2004
Safety of viral vectors for neurological gene therapiesKathleen A Maguire-Zeiss, Howard J Federoff
Journal of Neural Transmission (Vienna, Austria : 1996)|June 16, 2010
Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's diseaseKathleen A Maguire-Zeiss, Howard J Federoff
Annals of the New York Academy of Sciences|July 9, 2003
Convergent pathobiologic model of Parkinson's diseaseKathleen A Maguire-Zeiss, Howard J Federoff
International Journal of Molecular Sciences|September 20, 2013
Single-chain fragment variable passive immunotherapies for neurodegenerative diseasesLiang Huang, Xiaomin Su, Howard J Federoff
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 22, 2008
Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseasesKathleen A Maguire-Zeiss, Howard J Federoff
Pageof 17

Showing results (21-30 of 164) with videos related to

Sort By:
Pageof 17
Experimental Neurology|March 26, 2013
Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?Massimo S Fiandaca, Howard J Federoff
Science Translational Medicine|September 30, 2011
Disclosure of clinical trial results when product development is abandonedMichael A Rogawski, Howard J Federoff
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 3, 2014
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH directorHoward J Federoff, John E Wagner
Technology and Innovation|April 19, 2014
EDITORIAL: TECHNOLOGY, INNOVATION, AND HEALTHPaul R Sanberg, Howard J Federoff
Technology and Innovation|September 26, 2014
TECHNOLOGY AND INVENTIONPaul R Sanberg, Howard J Federoff
Current Opinion in Molecular Therapeutics|November 13, 2004
Safety of viral vectors for neurological gene therapiesKathleen A Maguire-Zeiss, Howard J Federoff
Journal of Neural Transmission (Vienna, Austria : 1996)|June 16, 2010
Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's diseaseKathleen A Maguire-Zeiss, Howard J Federoff
Annals of the New York Academy of Sciences|July 9, 2003
Convergent pathobiologic model of Parkinson's diseaseKathleen A Maguire-Zeiss, Howard J Federoff
International Journal of Molecular Sciences|September 20, 2013
Single-chain fragment variable passive immunotherapies for neurodegenerative diseasesLiang Huang, Xiaomin Su, Howard J Federoff
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 22, 2008
Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseasesKathleen A Maguire-Zeiss, Howard J Federoff
Pageof 17